To investigate the functional roles of individual HLA-DR residues in T cell recognition, transfectants expressing wild-type or mutant DR(o~, B1"0401) molecules with single amino acid substitutions at 14 polymorphic positions of the DI~1"0401 chain or 19 positions of the DRo~ chain were used as antigen-presenting cells for five T cell clones specific for the influenza hemagglutinin peptide, HA307-19. Of the six polymorphic positions in the DRB floor that were examined, mutations at only two positions eliminated T cell recognition: positions 13 (four clones) and 28 (one clone). In contrast, individual mutations at DRB positions 70, 71, 78, and 86 on the oe helix eliminated recognition by each of the dones, and mutations at positions 74 and 67 eliminated recognition by four and two clones, respectively. Most of the DRol mutations had minimal or no effect on most of the clones, although one clone was very sensitive to changes in the DRo~ chain, with loss of recognition in response to 10 mutants. Mutants that abrogated recognition by all of the clones were assessed for peptide binding, and only the B86 mutation drastically decreased peptide binding. Single amino acid substitutions at polymorphic positions in the central part of the DRB c~ helix disrupted T cell recognition much more frequently than substitutions in the floor, suggesting that DRB residues on the ol helix make relatively greater contributions than those in the floor to the ability of the DR(oe,~l*0401) molecule to present HA307-19. The data indicate that DRq8 residues 13, 70, 71, 74, and 78, which are located in pocket 4 of the peptide binding site in the crystal structure of the DR1 molecule, exert a major and disproportionate influence on the outcome of T cell recognition, compared with other polymorphic residues.
T
he MHC molecules on the cell surface have evolved the remarkable capacity to bind and present to T lymphocytes an extremely large number of structurally diverse peptides. Recognition of the appropriate peptide-class II complexes by the antigen-specific TCR leads to CD4 + T cell proliferation and a cascade of cellular immune responses. HLA class II molecules are highly polymorphic, and this structural polymorphism determines the distinct peptide-binding and antigen presentation characteristics of each molecule. However, the functional roles of individual residues in HLA class II molecules in peptide binding and T cell recognition have not been dearly defined. Elucidation of the ways in which class II residues interact with peptides and TCR may have important implications for understanding the function of the This study was presented in part as an abstract at the 19th annual meeting of the American Society for Histocompatibility and Immunogenetics, Phoenix, Arizona, 2-7 October, 1993. immune system, as well as for the treatment ofimmunologically mediated diseases.
Considerable progress has been made in the understanding of the structure of HLA class II molecules and the nature of class II-peptide interactions in recent years. Based on the crystal structure of HLA-A2 and the homologies between class I and II molecules, Brown et al. (1) proposed a structural model for class II molecules. The HLA-DR1 threedimensional structure indicates that this model is generally accurate (2) . In the initial DR1 crystal structure, the first domains of the ot and B chains form an antigen-binding groove composed of two c~ helices that rise above a floor of B strands. Importantly, the side chains of most of the polymorphic residues in the three hypervariable regions of the DRB chain point in toward the groove, where peptides are bound. At the level of the peptide molecule, several studies have defined residues crucial for binding to MHC and/or T cell recognition (3) (4) (5) (6) . Based on the relative spacing of such residues, it was concluded that peptide antigens were most likely to bind in an extended conformation. On the basis of results obtained by use of a combination of site-directed mutagenesis, direct peptide-binding studies, and single amino acid replacements in the peptide, Krieger et al. (7) described a model of peptide--class II interactions in which the peptide was bound in an NH2 to COOH orientation and in a fully extended conformation. The recently solved structure of the complex of DR1 and an antigenic peptide of influenza hemagglutinin (HA307-19) permits precise identification of the DR1 residues that make contacts with this peptide (8) and indicates that the model of peptide-class II interactions proposed by Krieger et al. (7) is remarkably accurate. However, structural data alone cannot define the relative functional importance of each DR residue whose side chain contacts peptide or is positioned such that it may interact with TCR. Further progress in the understanding of the contribution of individual class II residues to peptide binding and T cell recognition will require integration of functional data from analysis of class II mutants with structural data from additional class II-peptide complexes and, perhaps, class II-peptide-TCR complexes. Although future determination of the structure of class II-peptide-TCR complexes may permit resolution of some of the current ambiguities in the interpretation of structure-function studies, the structure of the trimolecular complex alone will not define the relative functional importance of individual class II residues that contact TCR or peptide.
In many previous studies of the structure-function relationships of MHC class II molecules, mutagenesis has been used to produce individual or multiple interallelic substitutions between two closely related alleles that differ by a few residues (9) (10) (11) . For example, the contributions of individual I-El3 residues to T cell responses were investigated by making mutations in El3 k, Eli b, and E/~ s at positions 29, 72, 75, and 79, which correspond to DRB positions 28, 71, 74, and 78 (1, 9) . Other studies analyzed the effects of mutations at larger numbers of positions in class II ot (12) or B (7, 13) chains. However, these previous studies still did not address the functional roles of other residues predicted to contribute to peptide binding and T cell recognition, because only a limited set of substitutions was analyzed and, most importantly, the contribution of only a single chain (or or/3) was investigated. In the current study, we have taken a broader approach by selecting for mutation 14 positions in the/3 chain and 19 positions in the c~ chain of a DR molecule. We selected for mutagenesis all those polymorphic DIL/3 positions that were predicted in the class II model to point into the peptide-binding groove: positions 9, 11, 13, 28, 30, and 37 in the floor and positions 57, 60, 67, 70, 71, 74, 78, and 86 on the c~ helix (1). We wondered whether the residue present at each of these polymorphic positions in the floor and o~ helix was equally likely to play an important role in T cell recognition of the class II-peptide complex. The Dlkot positions analyzed included 6 in the floor and 7 on the ot helix that were predicted in the model to point into the binding groove, and 6 on outer loops. This mutagenesis approach permits assessment of the functional involvement of individual residues, as well as comparisons of the contributions of residues in the floor versus those on the ol helix of each chain.
The objective of this study was to analyze the involvement of 33 individual residues of the DR(or,131*0401) molecule in T cell recognition and peptide binding. Importantly, this molecule is associated with susceptibility to the development and severity of rheumatoid arthritis (14) (15) (16) . Transfectants expressing wild-type or mutant DR(c~,fll*0401) molecules were used as APC for five DR(c~,fll*0401)-restricted T cell clones specific for HA307-19, a peptide of influenza hemagglutinin that can be bound and presented by multiple DR molecules. We found that mutations at six of eight positions on the fl chain c~ helix, but only two of six positions in the fl chain floor, affected T cell recognition. The ot chain mutations had minimal or no effects on most of the clones. The data demonstrate that T cell recognition of the DR(cr,fll*0401)-HA307-19 complex is much more sensitive to substitutions on the fl chain ol helix than to those in the fl chain floor. In addition, DtLt3 residues 13, 70, 71, 74, and 78, which are located in pocket 4 in the DR1 molecule (8), exert a major and disproportionate influence on T cell recognition of the peptide/DR complex, compared with other polymorphic residues. (20) . Site-directed mutagenesis of the DRA and DR(B1*0401) cDNAs was performed by the PCR overlap extension method (21) , and the mutants were sequenced to confirm the presence of the mutation and the absence of miscorporation as described (22) .
Materials and Methods
Transfection and mAbs. The mutant DRA or DRB cDNA was cotransfected with the complementary wild-type DRB or DRA cDNA into the DAP.3 subclone of class II-murine L fibroblasts as described (23) . The transfectants were cloned by limiting dilution or flow cytometric sorting, and cloned transfectants were used in T cell proliferation and peptide-binding assays. The class II expression levels of the transfectants were monitored by FACS | analysis (Becton Dickinson & Co., Mountain View, CA) with the anti-DR mAb L243 (ATCC) (24) , or HU-20 (obtained from Akemi Wakisaka, Hokkaido University School of Medicine, Sapporo, Japan) (25) for those transfectants whose L243 epitope was disrupted by the Dlkot mutations (26) ( Table 1) . Antibody binding to selected transfectants was also analyzed with the polymorphic anti-DR mAb AC.BM.50 (Dominique Charron, Institut Biomedical des Cordeliers, Paris, France) (27) , 21r5 (Michelle Letarte, Hospital for Sick Children, Toronto, Canada) (28) , and the anti-DR4 mAb GS359-13F10 (Susan Radka, Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA) (29) .
T Cell Clones and T Cell Proliferation Assay. Five influenza hemagglutinin peptide HA307-19-specific T cell clones were isolated from PBL of three DR(c~d31*0401) § individuals as described (7) . Briefly, HA307-19-specific and DR(ot,Bl*0401)-restricted T cell lines were established by incubating the PBL in vitro with HA307-19, and expanded with recombinant Ib2 (Genzyme Corp., Cambridge, MA). The T cell lines were cloned by limiting dilu- (30) . The peptide resin was biotinylated by coupling with succinimidyl-6-(biotinamido) hexanoate (Pierce Chemical Co., Rockford, IL) and purified by reverse-phase HPLC (Delta-Pak C-18; Waters, Milford, MA). The composition of the peptide was verified by amino acid analysis and fast-atom bombardment mass spectroscopy. For the peptide-binding assay (31) Dw4 Model. To better correlate the mutation data with threedimensional structure, a homology model of DP431"0401 was constructed by use of the coordinates (provided by Jerry Brown, Harvard University, Cambridge, MA) of the 3.2-A x-ray structure of DRBI*0101 (2) 
Results
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by DR(olj31"0401)-restricted T cell clones, 23 site-specific mutants of the DR(•1"0401) chain and 22 mutants of the DRo~ chain were produced and expressed with the complementary wild-type DRol or DR(/31"0401) chain on transfectants that were used as APC in T cell proliferation assays. The DP43 positions selected for mutagenesis were predicted in the class II model (1) to point into the peptide-binding groove. Importantly, most of these predictions were confirmed by the DR1 structures. In the DR1 crystal structures (2, 8) and our DR(c~,~I*0401) structural model, DI~3 residues 9, 11, 13, 28, 30, and 37 are located in one half of the floor of the antigen-binding groove with their side chains pointing up, and residues 57, 60, 67, 70, 71, 74, 78, and 86 are located on the ol helix with their side chains pointing either in toward the groove (residues 57, 60, 71, 74, 78, and 86) or up and in (residues 67 and 70) ( Fig. 1 A) . Residues in the floor with their side chains pointing up are potential peptide contact residues, whereas residues on the c~ helixes may be peptide and/or TCR contact residues, depending on the orientation of their side chains, the angle at which the TCR approaches the class II-peptide complex, and the bound peptide.
The substitution strategy was to change the residue in the DR(/31"0401) chain to the residue found at the corresponding positions in other DR alleles (Table 1) . In most cases, two substitutions were made at each position of DR(f31*0401). The first substitution at each position in the floor, plus those at positions 60 and 78 on the c~ helix, were made by changing the residue to the corresponding residue found in DR(/31"0701).
For the substitutions at positions 57, 67, 70, 71, 74, and 86 on the c~ helix, the residue of DR(31"0401) was changed to that found in other DR4 subtypes. To gain a broader picture of the functional roles of each residue, we also constructed a second set of substitutions with physical and chemical changes different than those of the first set of substitutions. DRot chain mutations were made at residues 7, 9, 11, 22, 24, and 31, which are located in the other half of the floor of the groove with their side chains pointing up, and at other DtLo~ residues located on the outer loops with their side chains pointing up (residues 15, 18, and 39), away (residues 36 and 42), or down (residue 19) (8) . Additional DRcx residues mutated are located on the ol helix with their side chains pointing into the groove (residues 65 and 72), up (residue 49), up and in (residue 55), away (residues 47 and 50), or down toward the floor (residue 66). The DRc~ residues were changed to the residues found at the corresponding positions in the I-Ecr DPc~, DQol, or I-Ac~ chain, as described (39) .
The five HA307-19-specific T cell dones used in this study were isolated from three DR(c~,Bl*0401)-positive donors, and each proliferated in response to HA307-19 presented by the DR(o~,/31"0401) transfectant. Because of the DtL/3 sequence similarities among the DR4 subtypes and DR1, we first investigated the restriction patterns of these clones by use of (Table 2 ). In the first domain, DR(31"0101) differs from DR(31"0401) at polymorphic positions in the floor and only at 371 on the a helix. Of the five clones, three are restricted only by DR(ol,31"0401), and the other two are also cross-reactive with DR(a,31*0405). T cell responses to the panel of DR(31"0401) mutant transfectants are shown in Fig. 2 . Overall, the T cell clones displayed five distinct reactivity patterns. Among the DR(31"0401) mutations made in the floor, both position 13 mutations abolished or significantly reduced the recognition of HA307-19 by four clones. The 328 D "~ H mutation also drastically decreased recognition by clone 33C6.6 only, whereas the con- whereas the nonconservative 371 K ~ E eliminated proliferation by four clones. The abilities of clones JB/12B/A10 and 3BC6.6 to recognize the 371 K ~ R mutant correlate well with the cross-reactivities of these clones with DR(o~, 31"0405), which has arginine at 371 ( Table 2 ). The 374 A ~ E and A --* Q mutations eliminated the response by four and two clones, respectively. Only clone KM1HA28 gave a minimal response at the highest peptide concentration to the B78 mutant. At 367, the conservative L -* I substitution reduced proliferation by only one clone, whereas the L --," F substitution eliminated recognition by two clones. These data indicate that DR3 o~ helix residues 70, 71, 74, 78, and 86 play crucial roles in the presentation of HA307-19. T cell responses to the DRo~ mutants are shown in Fig.  3 . Overall, the five clones displayed five different reaction patterns with the DRo~ mutant panel. Recognition of HA307-19 by JB/Y/A2 and KM1HA28 was abrogated by one of the DRoL chain mutations, and none of the DRc~ chain mutations abrogated recognition by JB/12B/A10. The single mutations at DRo~ positions 22, 24, and 31 and one of the multiple mutations at positions 47 and 66 abrogated or significantly decreased recognition by KM1HA27. The ell1 mutation was the only one that abrogated recognition by JB/Y/A2. In contrast to the four clones described above, clone 3BC6.6 was much more sensitive to substitutions in the DRoe chain; many of the DR~ mutations reproducibly affected the recognition by this clone. Among the DRo~ mutants, the position 24 and 31 mutations abrogated or significantly decreased recognition by three clones and shifted the dose-response curve of the remaining two clones to higher peptide concentrations. In contrast to the DR(B1*0401) chain, each of the mutations made in the floor residues of Dlq.el affected recognition of HA307-19 by at least one T cell clone. by multiple T cell clones. In contrast to the B70 Q -* R, 78 Y -* R, 78 Y -* V, and 86 G -~ V mutations that affected recognition by each of the five clones, the other mutants still presented the peptide efficiently to at least one T cell clone, documenting that these mutants were still able to bind the peptide. Binding of B-HA to the DR(B1*0401) 70 Q -~ K, 78 Y --~ V, and 86 G "--V mutants was analyzed by flow cytometry (Fig. 4 ). Other mutants with major effects on recognition were also included for comparison. B-GP, which is a DP-binding peptide (32) , and the DR(a, B1"0404) transfectant, which is a poor HA307-19 binder (40), were used as negative controls. The B86 G ---V mutation was the only one that almost abolished the binding of HA307-19 to the DR(a,/~1"0401) molecule. Interestingly, the c~24 F --~ H substitution increased binding of the negative control peptide gp41 582-595 to the DR molecule, providing additional evidence that c~24 interacts with peptides. The findings that most mutations did not prevent peptide binding are consistent with the DK1/HA peptide structure, in which hydrogen bonds between 12 nonpolymorphic and 3 polymorphic class II residues and main-chain atoms of the peptide make significant contributions to binding of the peptide (8) . In this context, it is interesting to note that our mutations at er and/371, which form such hydrogen bonds with the peptide in the DR1 structure, did not prevent peptide binding. The results of the T cell proliferation and peptidebinding studies are summarized in Table 3 .
Because most of the mutants still presented the peptide efficiently to at least one T cell clone, it is unlikely that these mutants have gross conformational changes. To address the possibility that the broad effects on T cell recognition caused by the mutations at DR(/31*0401) positions 70, 78, and 86 were due to gross alteration of the DR(or,/31*0401) conformation, these mutants, as well as the DRB position 13, 71, and 74 mutants and the DRo~ position 24 and 31 mutants, were analyzed with four polymorphic anti-DR mAbs. The HU-20, AC.BM.50, 21r5, and GS359-13F10 mAbs detect four distinct epitopes on DR4 molecules (41) (42) (43) . All of the 921 Fu et al. Peptide bindingn * The accessibility of a DR residue to peptide and TCR contacts is based on the DR1/HA307-19 structure (8) . p, peptide contact; t, potential TCR contact. S +, Proliferation levels at peptide concentration 1.0/~M >30% of that with wild-type Dw4H; _+, proliferation <30%; -, proliferation close to that with the negative control (DAPneo) . II +, HA307-319 binding levels >30% of that with the wild-type Dw4H; -, binding levels close to that with the negative controls.
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Functional Roles of DR(a,31*0401) Residues in T Cell Recognition paucity of effects on T cell recognition by substitutions in the floor in these previous studies was because the substitutions were too conservative. To address this possibility, two substitutions with distinct size and/or charge characteristics were introduced at five of the six positions in the floor of DR31"0401. However, only mutations at 3 floor residues 13 and 28 were found to affect T cell recognition. What is the basis for the finding that T cell recognition was not affected by substitutions in the DR31"0401 chain at four of the six polymorphic residues whose side chains point up from the floor into the peptide binding groove? One possibility is that the substitutions at positions 9, 11, 30, and 37, which affected recognition by none of the clones, resulted in less substantial size, charge, and/or chemical characteristic changes than those made at positions 13, 28, 67, 70, 71, 74, 78, and 86, which eliminated T cell recognition by one or more clones. This explanation seems unlikely because at least one substitution at each of positions 9, 11, 30, and 37 represented a very significant change. For example, the position 9 E ~ W substitution replaced the negatively charged side chain of glutamic acid with the bulkier, nonpolar side chain of tryptophan, and the position 11 V ~ S and V --~ G substitutions replaced the nonpolar side chain of valine with the polar side chain of serine or the much smaller glycine. The absence of effects by the position 9, 11, 30, and 37 substitutions are in contrast to the marked effect of the highly conservative c~ helix 371 K ---R substitution on three clones. Another possibility is that the side chains of residues 9, 11, 30, and 37 in the wild-type chain and/or the substituted residues do not contact the peptide. The absence of effects by substitutions at DK31"0401 residues 30 and 37 is consistent with the findings that these residues are not in contact with either the endogenous peptides or HA307-19 in the DR1 structures (2, 8) and suggests that the same is true when HA307-19 is bound to DR4. In contrast, however, the side chains of DR31"0101 residues 9 and 11 are in contact with the HA307-19 in the DR1 structure. The third possibility is that DR31"0401 residues 9, 11, 30, and/or 37 do make contacts with bound HA307-19, but the substitutions at these positions have little or no functional consequences because these interactions have no effect on the determinants recognized by the TCR.
Despite attempts to gather evidence to the contrary, we have consistently found the surprising result that T cell recognition of multiple DR-peptide complexes is more sensitive to interallelic substitutions on the ot helix than to analogous substitutions in the floor, suggesting that, as a group, residues at polymorphic positions in the floor make lesser contributions to T cell recognition of a specific peptide than those on the ot helix. These results underscore the necessity to complement structural data with in-depth functional analyses, in order to fully appreciate the relative functional roles of the different interactions revealed by crystallographic analysis. Polymorphic 3 residues in the floor are clearly important in the function of class II molecules. We envision that, in many cases, their contributions are operative more in determining the range of peptides that can be bound by a given molecule than in influencing the outcome of recognition of 923 Fu et al.
a peptide that has already been selected for binding, as in our analytical system. However, an example in which a class II B chain residue in the floor determined peptide binding has been reported (9) . What are the mechanisms by which the substitutions at DR(B1*0401) positions 13, 28, 67, 70, 71, 74, 78 The position 86 mutation probably affected T cell recognition by causing a marked decrease in the ability of the molecule to bind the peptide. These findings are consistent with previous reports showing that the dimorphism at position 86 of the DR3 chain is critical in peptide binding and T cell recognition (7, 40, (44) (45) (46) . On the other hand, the natural dimorphism at 3 position 86 does not seem to be the only factor that determines the binding of HA307-19 to DR molecules. For example, DR(c~,31"1301) and DR(or,31*1401) bind HA307-19 at high levels but have valine at position 86, and DR(or,31*09011), which has glycine at position 86, binds HA307-19 poorly (47) . These data suggest that polymorphic residues in other regions, in addition to several conserved residues (8) , also contribute to the binding of HA307-19 by some molecules. In the DR1/HA307-19 structure, residues in a deep pocket in the peptide-binding site, consisting of 386 and c~24, c~31, oe32, o~43, 385, 389, and 390, contact tyrosine 309 of the peptide (8) . This pocket is likely to be similar between DR(or,31*0101) and DR(or,B1*0401), because their sequences in this region are identical. Interestingly, mutations at DRc~ positions 24 and 31 had major effects on T cell recognition but not on HA307-19 binding. Although these DRoe residues were not essential for HA307-19 anchoring, they are likely to contribute to the conformation of the pocket and/or the anchored peptide. The spatial relationships of DR386, c~24, and ot31 are highlighted in Fig.  1 , B and C.
Residue 370 played a crucial role in recognition by each of the clones studied. In the DR1/HA307-19 structure, DR31"0101 residue 70 glutamine contacts peptide residue 312 (glutamine) and is exposed such that it might also interact with TCR (8). In our DR(ol,31"0401) model, the side chain of 370 glutamine points up and in over the peptidebinding groove such that it might contact both peptide and TCR. In addition, antibody-binding data suggest that the side chain of DR31"0401 residue 70 is solvent accessible; the 70 Q---D mutation in 31"0401 eliminated binding of two mAbs but did not affect binding of several others (48) . In the initial DR1 structure and our DR(or,31*0401) model, residue 67 is located at the highest point of the 8 chain a helix, making it a prominent feature of the top surface of the molecule. In contrast, residue ~67 contacts peptide leucine 315 and is exposed for possible TCR interaction in the DR1/HA307-19 structure. Therefore, DRBI*0401 residues 67 and 70 likely affected T cell recognition in our studies by altering peptide conformation and/or a critical TCR contact.
The side chains of ~ residues 13, 28, 71, 74, and 78 point into the peptide-binding groove in the DR1 structures and the Dw4 model (Fig. 1, B and C) . The side chains of DR3 residues 13, 70, 71, 74, and 78, as well as c~9, form a shallow pocket, referred to as pocket 4, which is occupied by peptide residue 312 glutamine in the DR1/HA307-19 structure (8).
In addition, DR3 residue 28 makes contact with peptide residue 315 in the DR1/HA307-19 structure. The fact that DR31"0401 and 0101 differ only at positions 13 and 71 within pocket 4 suggests that the shape of this pocket in DtL81*0401 is likely to be similar to that found in DRBI*0101. In the DR1/HA307-19 structure (8), residue 13 is located in the floor of the peptide-binding groove below the peptide, indicating that it is not accessible to TCR contact. The side chains of residues 74 and 78 point down toward the peptide-binding groove and contact the peptide, but they were not felt to be exposed for potential TCR contact (8) . In the context of these structural data, our findings that substitutions at DIL81*0401 positions 13, 74, and 78 eliminated recognition by multiple clones, whereas peptide binding was preserved, indicate that these mutations most likely affected T cell recognition by altering the conformation of the bound peptide instead of by altering TCR contacts. Because 871 is also exposed in the DR1/HA307-19 structure, substitutions at this position may affect T cell recognition by altering peptide conformation and/or a TCR contact. The likelihood that the mutations at all or some of DR3l*0401 residues 13, 28, 70, 71, 74, and 78 affected T cell recognition by altering peptide conformation are consistent with recent studies that indicate that TCR recognition of the class II-peptide complex is primarily determined by the TCR CDR3-peptide interaction (49) . Taken together, the functional and structural data indicate that DR~1"0401 residues 13, 70, 71, 74, and 78 in pocket 4 contribute to a functional unit that has a disproportionately large influence on the outcome of T cell recognition, compared with the other polymorphic positions. In the context of the functional data, the proximity and arrangement of residues 13, 70, 71, 74, and 78 in the Dw4 model are impressive (Fig. 1, B and C) .
The DRa mutations had minimal or no effects on three of the clones, an intermediate effect on one clone, and widespread, significant effects on one clone. The DRa substitutions at positions 22, 42, 49, 50, 55, 65 , and 72 are relatively conservative, which may contribute to the lack of effects on T cell recognition with these DRa mutants. Mutations at oe24 and 31, which, as noted above, are located in the 886 pocket, affected the largest number of clones. The sensitivity of clone 3BC6.6 to 11 mutations scattered throughout DRc~ is noteworthy, especially in contrast to the reactivity patterns of the other four clones to the DRa mutants and the localized effects of the DR(~/1"0401) mutants on 3BC6.6. Proliferation of 3BC6.6 was eliminated or reduced by each of the 6 mutations in the floor of DRop. Because these mutations did not prevent peptide binding, they probably caused changes in peptide conformation to which 3BC6.6 is exquisitely sensitive but which are tolerated by most of the other clones. Interestingly, mutations at ol positions 15, 18, and 39 that affected recognition by this clone are located on outer loops away from the peptide-binding groove, raising the possibility that the area of contact of the TCR with class II may, in some cases, extend beyond the o~ helices.
Our findings that substitutions at multiple positions on the DR8 chain ol helix frequently eliminated T cell recognition are consistent with previous studies in murine (11, 50, 51) and human (52, 53) systems that found that 8 chain c~ helix residues, especially those in the central portion of the helix, are important for recognition. However, the current study adds the important perspective that these DIL8 chain oe helix residues influence T cell recognition far more frequently than other highly polymorphic residues in the same chain. These residues, especially those in pocket 4, appear to be uniquely positioned to influence features of the class II-peptide complex that are required for T cell recognition by affecting peptide conformation and/or providing critical TCR contacts. Influences on peptide conformation by these B chain a helix residues may more frequently affect T cell recognition than those on the floor because the conformational effects are more pronounced at the surface of the peptide contacted by TCR.
